FDA warns of hepatotoxicity risk with Xenical and Alli (orlistat) - MPR
Links shared publicly online about this topic.
- 1,797total visits
FDA warns of hepatotoxicity risk with Xenical and Alli (orlistat) - MPR
empr.com —
The FDA has notified healthcare professionals and consumers that it is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat, which is marketed in the U.S. as Xenical (from Roche) and Alli (from GlaxoSmithKline).
View full resource at empr.com
Tags: Obesity Medication, Healthcare, FDA, Xenical, GlaxoSmithKline
Most Recently Shared on August 25, 2009 at 5:41 pm By:
MPR News: FDA warns of hepatotoxicity risk with Xenical and Alli (orlistat): The FDA has notified healt.. http://bit.ly/BdTnB
Advertisement
